CME Opportunity: Join #DukeDebates2024, presented by #DukeCancerNetwork in collaboration with @DukeCancer. April 12-14, 2024, Hilton Head, SC Register here: https://t.co/yOJ9bo9fc3 CME credit available. Earn up to 12 MOC Part 2 points. #DukeCancerInstitute #MedEd

Ask your doctor if you are considered high risk by the CLLIPI score. If so, you may qualify for this exciting study. #CLL @SWOG @BrianHill_MDPhD @mshadman @anthonymatomd @dbranderMD @DanilovLab

Outstanding commentary by ⁦@DebbieMStephens⁩ from ⁦@huntsmancancer⁩ on the recent publication on the ELEVATE-RR study comparing ibrutinib and acalabrutinib in R/R CLL in ⁦@JCO_ASCO⁩

Just out - our multicenter effort to dissect comorbidities in CLL ⁦@mshadman⁩ ⁦@DrDanPersky⁩ ⁦@dbranderMD⁩ ⁦@matthew_mei⁩ ⁦@jonathonbcohen⁩ ⁦@KrishPatelMD⁩ ⁦@BrianHill_MDPhD⁩ ⁦@DebbieMStephens⁩

Thanks to the @CllSociety for all you do for our patients. Happy New Year!

Important MURANO tox ax @anthonymatomd @jeff_sharman et al 28% premature d/c VR<2y ⬇️ PFS in prem d/c ven for any reason (PD excluded;p<0.0001)+due to AE Interrupt for AE 69% / dose ⬇️ 23% both no impact on PFS/OS Tox mx+continued Rx important for VenR PFS outcome #CLL #lymsm

#ASH20 poster by @LindsayReinMD @DukeHMCT @dukemedicine @DukeCancer Phase I trial incorporating NK cells for patients w/ #CML & MRD after TKI therapy. #leusm https://t.co/skRtQa5DCw

There may not have been an official ASH run this year, but anyone else still get in their #FauciFour ? If daily running is the secret to Dr Fauci leading the nation through this chaos, may I never stop. Also, the San Diego skyline has nothing on my view. #IRunForASH

@DukeHMCT @DukeFellows @DukeCancer

Flashback Friday and my upcoming first Twitter-versary. This tweet from an amazing #cll leader, along with a little help from @chadinabhan and @anthonymatomd finally got me on board. Looking forward to #ash20 highlights and my first ash on Twitter.

To teach is to learn, twice And thankful for this opportunity from #ASH20, twice - to learn from so many others but also to work on this with an amazing fellow @DukeFellows, Dr Ashley Hanlon @amilliga, that has taught me so much and co authored this chapter #dukefamily

We are so excited to welcome @_joycehwang @andrewpeseski @FahminB_MDPhD Drs. Kathrine DiNardo, Cameron Oswalt, Grayce Selig, and Cameron Wood to the Duke Heme/Onc Fellowship Program! We are so excited to have you join our wards and clinics in July 2021! @DukeCancer @dukemedicine

Intolerance is a failure of the medication for that given patient, patients don’t fail therapy. Grateful to be a part of this collaborative effort @DukeHMCT and for all trials aimed at the unmet need of intolerance. @anthonymatomd @AndreaSitlinger and many others

Please see our publication of the largest cohort of patients #Hodgkin transformation in #CLL patients. https://t.co/WF2Xjcdppf Planning more research in this patient population. Thanks for a great collaborative effort. @huntsmancancer @UUtah. @UofUHealth

Outcome of #Hodgkin arising from #CLL. collaboration led by @DebbieMStephens. https://t.co/4Tt6KvAiao @dbranderMD @DrMDavids @anthonymatomd @fredhutch @SeattleCCA

🎉🎉 Congratulations to @BarbAlexanderMD, who will be the new president of @IDSAInfo. "The critical role of ID physicians & scientists has never been more apparent as it is today."

every point exactly, @JasAWebb - easy to feel defeated hearing this news, but will take that energy and use it to inspire action towards the many challenges that face us...